Targeting toll-like receptors for drug development: a summary of commercial approaches

Toll‐like receptors (TLRs) play a fundamental role in recognizing infectious and noxious agents as well as products of tissue damage. They are capable of initiating both protective and damaging inflammatory and immune responses. Several biotechnology and pharmaceutical companies have programmes to d...

Full description

Saved in:
Bibliographic Details
Published inImmunology and cell biology Vol. 85; no. 6; pp. 490 - 494
Main Author Gearing, Andrew J H
Format Journal Article
LanguageEnglish
Published United States Nature Publishing Group 01.08.2007
Blackwell Science Ltd
Subjects
Animals
Clinical Trials as Topic
commercial approaches
Drug Design
drug targets
Humans
Toll-Like Receptors - antagonists & inhibitors
toll‐like receptors
Online AccessGet full text

Cover

More Information
Summary:Toll‐like receptors (TLRs) play a fundamental role in recognizing infectious and noxious agents as well as products of tissue damage. They are capable of initiating both protective and damaging inflammatory and immune responses. Several biotechnology and pharmaceutical companies have programmes to develop new drugs that are either: agonists of TLRs to enhance immune responses against tumours and infectious agents, or to correct allergic responses; or antagonists designed to reduce inflammation due to infection or autoimmune disease. This article reviews the commercial approaches being undertaken to develop new TLR drugs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0818-9641
1440-1711
DOI:10.1038/sj.icb.7100102